At the June 22 meeting of the ACIP, preliminary data were shared regarding the effectiveness of FluMist® Quadrivalent during the 2015-2016 influenza season. Based on a review of these data, the ACIP issued an interim recommendation that FluMist Quadrivalent should not be used in any setting for the 2016-2017 influenza season.
Our goal in sharing this information with you is to ensure you are fully informed as you plan for the upcoming 2016-2017 influenza season. AstraZeneca will continue to evaluate the decision of making FluMist Quadrivalent available within the United States in the 2016-17 influenza season and will be providing additional information. At this time you may reach out to your FluMist Quadrivalent distributor to make any order modifications you feel are necessary.
The APP has pulled together some resources to help your practice through the transition. Click here for more details.